Benefits Of Imprint's Techology to Complex Formulations

Complex formulations and difficult-to-deliver therapies can now be administered painlessly, effectively, and without specialised skills, using the expertise and innovative systems available at Imprint. This is good news for

• development of better complex injectable formulations
• marketing of complex injectable formulations–

Development of better methods to deliver complex formulations

Imprint's technology enhances the delivery of many complex injectable formulations including

• microparticulates
• viscous and pegylated solutions
• hydrogels
• mammalian cells in support media
• emulsions
• long-acting (depot) drugs
• high compliance medications.

 All the above can sometimes be poorly delivered by even the largest acceptable needles. Pharmaceutical companies can now source solutions to complex problems with inejctables from Imprint. 

 The Imprint technology will help formulators to:

• overcome technical delivery problems
• deliver higher doses
• develop longer acting therapies
• achieve higher blood concentrations
• reduce the force to inject.

Marketing of Complex Injectable Formulations

Complex formulations are a challenge for marketers. They require large needles to deliver, which appear threatening and cumbersome.  This puts them at an immediate disadvantage when compared to products delivered by smaller needles.  The impact is easily measured and profound.

Imprint's technology significantly ameliorates the disadvantages of complex viscous formulations, enabling their positive side to shine. For example:

• Smaller needles are undoubtedly more attractive to patients than large needles.
• The reduced force needed to inject enables a wider range of patients to use them, e.g. arthritic patients and the elderly.

Our record

 Imprint has an impressive track record.  We have dealt many of the long acting therapies currently being developed.  Whilst not all these have proceeded to the clinic, Imprint has develop experience second to none in the area of complex injectables.   Imprint is currently helping five pharmaceutical companies to develop complex injectable products.